Literature DB >> 15028303

High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.

S Roka1, M Rudas, S Taucher, P Dubsky, T Bachleitner-Hofmann, D Kandioler, M Gnant, R Jakesz.   

Abstract

INTRODUCTION: Recommendations for adjuvant treatment of DCIS after breast conservation are controversial. We tried to identify further risk factors in a retrospective study of our own practice. PATIENTS AND METHODS: Three hundred and thirty-two patients treated by breast conservation between 1978 and 2001 at the Department of General Surgery, University of Vienna were analysed. Tumour size, nuclear grade, hormone receptors, p53, her-2/neu, multifocality, microinvasion and post-operative therapy (irradiation, tamoxifen or combination) were analysed for their influence on breast recurrence.
RESULTS: Overall recurrence rate was 6.1% (8/132). For patients with DCIS showing high nuclear grade or negative estrogen receptor the risk for development of ipsilateral breast recurrence is significantly higher. Newer factors like p53 and her-2/neu do not have any prognostic significance. No recurrence was observed in patients treated by post-operative irradiation and tamoxifen.
CONCLUSION: Nuclear grade remains the most significant factor for breast recurrence after DCIS. Hormone receptor status identifies a subset of patients with more favourable prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028303     DOI: 10.1016/j.ejso.2003.11.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  16 in total

1.  Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence.

Authors:  Xin Zhou; Alan K Meeker; Kepher H Makambi; Ourania Kosti; Bhaskar V S Kallakury; Mary K Sidawy; Christopher A Loffredo; Yun-Ling Zheng
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

2.  The influence of clinicopathological features on the predictive accuracy of conventional breast imaging in determining the extent of screen-detected high-grade pure ductal carcinoma in situ.

Authors:  L Hayward; R S Oeppen; A V Grima; G T Royle; C M Rubin; R I Cutress
Journal:  Ann R Coll Surg Engl       Date:  2011-07       Impact factor: 1.891

3.  HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence.

Authors:  Thomas J O'Keefe; Sarah L Blair; Ava Hosseini; Olivier Harismendy; Anne M Wallace
Journal:  Cancer Prev Res (Phila)       Date:  2020-06-03

4.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

Review 5.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

6.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

7.  Clinical experience of patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery plus radiotherapy: a preliminary report.

Authors:  Ji-Young Jang; Mi-Ryeong Ryu; Sung-Whan Kim; Chul-Seung Kay; Yeon-Sil Kim; Yoon-Kyeong Oh; Hyung-Chul Kwon; Sei-Chul Yoon; Woo-Chan Park; Byung-Joo Song; Se-Jeong Oh; Sang-Seol Jung; Jong-Man Won; Seung-Nam Kim; Su-Mi Chung
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

8.  Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Authors:  Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Breast Cancer Res Treat       Date:  2013-06-18       Impact factor: 4.872

Review 9.  Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Authors:  Kevin Shee; Kristen E Muller; Jonathan Marotti; Todd W Miller; Wendy A Wells; Gregory J Tsongalis
Journal:  Am J Pathol       Date:  2018-10-29       Impact factor: 4.307

10.  Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial.

Authors:  Mangesh A Thorat; Pauline M Levey; J Louise Jones; Sarah E Pinder; Nigel J Bundred; Ian S Fentiman; Jack Cuzick
Journal:  Clin Cancer Res       Date:  2021-03-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.